Cargando…
Serum IgA Fc effector functions in infectious disease and cancer
Immunoglobulin (Ig) A is the most abundant antibody isotype present at mucosal surfaces and the second most abundant in human serum. In addition to preventing pathogen entry at mucosal surfaces, IgA can control and eradicate bacterial and viral infections through a variety of antibody‐mediated innat...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217208/ https://www.ncbi.nlm.nih.gov/pubmed/31785006 http://dx.doi.org/10.1111/imcb.12306 |
_version_ | 1783532570753892352 |
---|---|
author | Davis, Samantha K Selva, Kevin J Kent, Stephen J Chung, Amy W |
author_facet | Davis, Samantha K Selva, Kevin J Kent, Stephen J Chung, Amy W |
author_sort | Davis, Samantha K |
collection | PubMed |
description | Immunoglobulin (Ig) A is the most abundant antibody isotype present at mucosal surfaces and the second most abundant in human serum. In addition to preventing pathogen entry at mucosal surfaces, IgA can control and eradicate bacterial and viral infections through a variety of antibody‐mediated innate effector cell mechanisms. The role of mucosal IgA in infection (e.g. neutralization) and in inflammatory homeostasis (e.g. allergy and autoimmunity) has been extensively investigated; by contrast, serum IgA is comparatively understudied. IgA binding to fragment crystallizable alpha receptor plays a dual role in the activation and inhibition of innate effector cell functions. Mounting evidence suggests that serum IgA induces potent effector functions against various bacterial and some viral infections including Neisseria meningitidis and rotavirus. Furthermore, in the era of immunotherapy, serum IgA provides an interesting alternative to classical IgG monoclonal antibodies to treat cancer and infectious pathogens. Here we discuss the role of serum IgA in infectious diseases with reference to bacterial and viral infections and the potential for IgA as a monoclonal antibody therapy. |
format | Online Article Text |
id | pubmed-7217208 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-72172082020-05-13 Serum IgA Fc effector functions in infectious disease and cancer Davis, Samantha K Selva, Kevin J Kent, Stephen J Chung, Amy W Immunol Cell Biol Reviews Immunoglobulin (Ig) A is the most abundant antibody isotype present at mucosal surfaces and the second most abundant in human serum. In addition to preventing pathogen entry at mucosal surfaces, IgA can control and eradicate bacterial and viral infections through a variety of antibody‐mediated innate effector cell mechanisms. The role of mucosal IgA in infection (e.g. neutralization) and in inflammatory homeostasis (e.g. allergy and autoimmunity) has been extensively investigated; by contrast, serum IgA is comparatively understudied. IgA binding to fragment crystallizable alpha receptor plays a dual role in the activation and inhibition of innate effector cell functions. Mounting evidence suggests that serum IgA induces potent effector functions against various bacterial and some viral infections including Neisseria meningitidis and rotavirus. Furthermore, in the era of immunotherapy, serum IgA provides an interesting alternative to classical IgG monoclonal antibodies to treat cancer and infectious pathogens. Here we discuss the role of serum IgA in infectious diseases with reference to bacterial and viral infections and the potential for IgA as a monoclonal antibody therapy. John Wiley and Sons Inc. 2020-01-19 2020-04 /pmc/articles/PMC7217208/ /pubmed/31785006 http://dx.doi.org/10.1111/imcb.12306 Text en © 2019 The Authors. Immunology & Cell Biology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Reviews Davis, Samantha K Selva, Kevin J Kent, Stephen J Chung, Amy W Serum IgA Fc effector functions in infectious disease and cancer |
title | Serum IgA Fc effector functions in infectious disease and cancer |
title_full | Serum IgA Fc effector functions in infectious disease and cancer |
title_fullStr | Serum IgA Fc effector functions in infectious disease and cancer |
title_full_unstemmed | Serum IgA Fc effector functions in infectious disease and cancer |
title_short | Serum IgA Fc effector functions in infectious disease and cancer |
title_sort | serum iga fc effector functions in infectious disease and cancer |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217208/ https://www.ncbi.nlm.nih.gov/pubmed/31785006 http://dx.doi.org/10.1111/imcb.12306 |
work_keys_str_mv | AT davissamanthak serumigafceffectorfunctionsininfectiousdiseaseandcancer AT selvakevinj serumigafceffectorfunctionsininfectiousdiseaseandcancer AT kentstephenj serumigafceffectorfunctionsininfectiousdiseaseandcancer AT chungamyw serumigafceffectorfunctionsininfectiousdiseaseandcancer |